北大医药子公司与国际医院合作终止，面临主营业务中止风险

Core Viewpoint - The company faces a significant risk of a complete halt in its main business operations due to the termination of its long-term service contract with Peking University International Hospital, which is expected to lead to substantial revenue and profit declines starting in 2025 [1] Financial Impact - The termination of the business cooperation is projected to result in a sales revenue decrease of approximately 600 million yuan and a net profit reduction of about 40 million yuan in 2025 [1] - From 2026 onwards, the company may experience a further revenue decline of around 1.027 billion yuan and a net profit decrease of approximately 68.69 million yuan [1] Strategic Direction - The company is exploring new transformation directions for its subsidiary, Beijing Beiyi Medicine, but this process carries uncertainties [1] - There is a risk of business closure or transition if the transformation efforts do not succeed [1]